If you asked your doctor about hormone replacement therapy in the early 2000s, there is a good chance you were told to avoid it. The concern was cancer. The concern was heart disease. The message was: the risks outweigh the benefits.
That message came from a large study called the Women's Health Initiative (WHI), published in 2002. The study was stopped early. The headlines were alarming. And for a generation of women, HRT became something to fear rather than consider.
The problem is that the study had significant limitations that were not widely communicated at the time. And in the years since, researchers have gone back through the data, published follow-up analyses, and arrived at a very different picture, one that most women navigating perimenopause and menopause today have never been told about.
This article is not about telling you what to do. It is about making sure you have the full picture, so that if HRT is right for you, fear based on outdated information is not the reason you miss out on it.
The Women's Health Initiative was a large randomized controlled trial that looked at a specific type of combined hormone therapy: conjugated equine estrogen combined with a synthetic progestin called medroxyprogesterone acetate (MPA).
The study population was important. The average participant age was 63. Many had pre-existing cardiovascular conditions. They were, on average, more than a decade past menopause. This is not the population most women think of when they consider starting HRT.
The headline finding was a small increase in breast cancer risk in the combined therapy arm, and an increase in cardiovascular events. Both of these findings have since been heavily qualified.
The breast cancer finding:The absolute risk increase was small. The original trial showed roughly 8 additional cases of breast cancer per 10,000 women per year in the combined HRT group compared to placebo. More recent analyses have found that the risk varies significantly depending on the type of progestogen used, and that some forms carry little to no measurable increase.
The cardiovascular finding:A key reanalysis, the "timing hypothesis," showed that the cardiovascular risk identified in the original study was largely specific to women who started HRT long after menopause. Women who began therapy within ten years of menopause or before age 60 did not show the same pattern and, in some analyses, showed a reduction in cardiovascular risk.
Since 2002, there have been multiple large-scale analyses, updated guidelines, and a significant shift in clinical consensus among menopause specialists. The following reflects the current state of evidence.
Estrogen is one of the most effective interventions available for preventing osteoporosis. Multiple studies and meta-analyses confirm that HRT significantly reduces bone loss and fracture risk in postmenopausal women.
The Menopause Society (formerly NAMS) and the British Menopause Society both now recognize that for healthy women under 60, or within ten years of menopause, HRT does not increase cardiovascular risk and may reduce it. This is consistent with the "timing hypothesis" mentioned above, which has accumulated substantial supporting evidence since it was first proposed.
Hot flashes, night sweats, and sleep disruption are the most commonly recognized symptoms of menopause. Hormone therapy remains the most effective treatment for vasomotor symptoms, with a large body of evidence supporting its use for women with moderate to severe symptoms.
Evidence here is still developing, but several studies suggest that estrogen may have a protective effect on cognitive function when used during the menopause transition. Some research indicates that HRT may reduce the risk of depression in perimenopause, a period already associated with increased vulnerability to mood changes.
Vaginal dryness, urinary urgency, and recurrent urinary tract infections are common in menopause and significantly affect quality of life. Local estrogen therapy for these symptoms has an excellent safety profile and is effective even in women who may not be candidates for systemic HRT.
This is often the point where women stop considering HRT entirely. It is worth looking at the numbers carefully.
For most women starting HRT in perimenopause or early menopause, the current evidence suggests the following:
None of this means the risk conversation should be skipped. It means it should happen with full information, tailored to your personal health history, not based on a 2002 headline.
If the evidence has shifted this significantly, why are women still leaving appointments without a proper conversation about HRT?
Part of the answer is time. A standard primary care visit does not always allow for the kind of nuanced discussion that menopause care requires. Guidelines have evolved, but clinical practice does not always keep pace. Many doctors trained during the period when the WHI findings were at their most alarming, and some have not revisited the topic in depth since.
Part of the answer is also that menopause has historically been under-resourced in medical training. A 2019 survey found that OB-GYN residents received an average of less than three hours of menopause-specific education. General practitioners often receive less.
This is not a failure of individual clinicians. It is a structural gap in how midlife women's health has been prioritized, and it is part of what has changed as awareness has grown and as menopause specialists and advocacy organisations have pushed for updated guidance.
HRT is not right for every woman. There are genuine contraindications, including a personal history of certain hormone-sensitive cancers, undiagnosed vaginal bleeding, active liver disease, and active blood clots or stroke.
But for many women who are told "HRT isn't for you" without a detailed discussion, the conversation has simply not gone deep enough. Questions worth raising with a clinician trained in menopause care include:
Getting answers to these questions requires a clinician who has current knowledge of the evidence and time to apply it to your individual situation. That is not always easy to find in a standard appointment, which is part of why specialist telehealth options for menopause care have become increasingly important for women who feel their concerns are not being addressed.
The conversation around HRT changed substantially after 2002, and then it changed again as researchers went back and looked more carefully at the evidence.
For women in perimenopause and early menopause, the current guidance from leading menopause societies supports HRT as a safe and effective option for most healthy women with significant symptoms, when started at the right time and tailored to the individual.
You deserve that conversation. Not a reflex no. Not reassurances that symptoms will pass. A real, evidence-based discussion about what is happening in your body and what the options are.
That is what good menopause care looks like. And it is available.
Sources
Writing Group for the Women's Health Initiative Investigators.Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women's Health Initiative Randomized Controlled Trial.JAMA. 2002.
Manson JE et al.Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials.JAMA. 2013.
Fournier A et al.Unequal Risks for Breast Cancer Associated with Different Hormone Replacement Therapies: Results from the E3N Cohort Study.Breast Cancer Research and Treatment. 2008.
Hodis HN et al.Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing.Cancer Journal. 2022.
Rossouw JE et al.Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause.JAMA. 2007.
Weitzmann MN et al.Estrogen Deficiency and Bone Loss: An Inflammatory Tale.Journal of Clinical Investigation. 2006.
The Menopause Society.The 2023 Menopause Society Position Statement on Hormone Therapy.Menopause. 2023.
Henderson VW et al.Menopause and Mitochondria: Windows Into Estrogen Effects on Alzheimer’s Disease Risk and Therapy.Progress in Molecular Biology and Translational Science. 2010.
Soares CN et al.Efficacy of Estradiol for the Treatment of Depressive Disorders in Perimenopausal Women: A Double-Blind, Randomized, Placebo-Controlled Trial.Archives of General Psychiatry. 2001.
Allen NE et al.Moderate Alcohol Intake and Cancer Incidence in Women.Journal of the National Cancer Institute. 2009.
Kaunitz AM et al.Management of Menopausal Symptoms.Obstetrics and Gynecology. 2015.
This article is for informational purposes only and is not medical advice. Always consult a qualified clinician to discuss your health and treatment options.
Hemma Wellness is not a medical practice. All clinical services are provided by licensed healthcare professionals through our partner network. Individual results may vary.
These statements have not been evaluated by the Food and Drug Administration. Compounded medications have not been evaluated or approved by the FDA for safety, efficacy, or quality. This content is intended for informational purposes only and does not constitute medical advice.
Labs are billed separately when ordered by your clinician, except where noted in specific program descriptions.
